Plasma YKL-40

Nielsen, Anders Rinnov; Erikstrup, Christian; Johansen, Julia S.; Fischer, Christian P.; Plomgaard, Peter; Krogh-Madsen, Rikke; Taudorf, Sarah; Lindegaard, Birgitte; Pedersen, Bente Klarlund

doi:10.2337/db08-0182

Cited by 134 publications

(119 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, plasma CHI3L1 levels are upregulated in patients with insulin resistance and type 2 diabetes, independently of obesity [89]. However, the physiological role and source of circulating CHI3L1 remains largely unknown.…”

Section: Myokines and Metabolic Regulationmentioning

confidence: 99%

Myokines in insulin resistance and type 2 diabetes

et al. 2014

View full text Add to dashboard Cite

Skeletal muscle represents the largest organ of the body in non-obese individuals and is now considered to be an active endocrine organ releasing a host of so-called myokines. These myokines are part of a complex network that mediates communication between muscle, the liver, adipose tissue, the brain and other organs. Recent data suggest that myokines regulated by muscle contraction may play a key role in mediating the health-promoting effects of regular physical activity. Although hundreds of myokines have recently been described in proteomic studies, we currently have a rather limited knowledge of the specific role these myokines play in the prevention of insulin resistance, inflammation and associated metabolic dysfunction. Several myokines are known to have both local and endocrine functions, but in many cases the contribution of physical activity to the systemic level of these molecules remains as yet unexplored. Very recently, novel myokines such as irisin, which is thought to induce a white to brown shift in adipocytes, have gained considerable interest as potential therapeutic targets. In this review, we summarise the most recent findings on the role of myokines in the regulation of substrate metabolism and insulin sensitivity. We further explore the role of myokines in the regulation of inflammation and provide a critical assessment of irisin and other myokines regarding their potential as therapeutic targets.

show abstract

Section: Myokines and Metabolic Regulationmentioning

confidence: 99%

Myokines in insulin resistance and type 2 diabetes

et al. 2014

View full text Add to dashboard Cite

show abstract

“…YKL-40 has been regarded as an acute-phase protein, because its plasma concentration increases more than 25% after an inflammatory stimulus, but YKL-40 is different from and independent of C-reactive protein (CRP). Increased plasma YKL-40 concentrations have been seen in patients with diseases characterized by inflammation and ongoing tissue remodeling, such as ischemic cardiovascular diseases, cancer, diabetes, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, pneumonia, and liver fibrosis (1)(2)(3)(4)(5)(6)(7).…”

mentioning

confidence: 99%

Plasma YKL-40 and Total and Disease-Specific Mortality in the General Population

et al. 2010

View full text Add to dashboard Cite

BACKGROUND Increased plasma YKL-40 is associated with short-term survival in patients with cardiovascular disease and cancer. We tested the hypothesis that increased plasma YKL-40 is associated with total and disease-specific mortality in the general population. METHODS We measured plasma YKL-40 in 8899 study participants, aged 20–95 years, in the Copenhagen City Heart Study from the Danish general population who were followed for 16 years: 3059 died, 2158 had ischemic cardiovascular disease, 2271 had cancer, and 2820 had other diseases associated with increased YKL-40. Hazard ratios for early death and absolute 10-year mortality rates were calculated according to plasma YKL-40 percentile groupings computed within sex and age decade: 0%–33%, 34%–66%, 67%–90%, 91%–95%, and 96%–100%. RESULTS Median survival age decreased from 83 years for participants with plasma YKL-40 in category 0%–33% to 69 years in category 96%–100% (trend, P < 0.0001). Risk of early death was increased (multifactorially adjusted hazard ratios) by 10% for YKL-40 category 34%–66%, by 30% for 67%–90%, by 70% for 91%–95%, and by 90% for 96%–100% vs YKL-40 category 0%–33% (trend, P < 0.0001). Corresponding increases in participants with ischemic cardiovascular disease were 10%, 20%, 80%, and 60% (P < 0.0001); in those with cancer were 10%, 20%, 50%, and 70% (P < 0.0001); and in those with other diseases were 10%, 20%, 40%, and 60% (P < 0.0001). Highest absolute 10-year mortality rates were 78% and 90% in women and men, respectively, who were >70 years old, smoked, and were in YKL-40 category 96%–100%. CONCLUSIONS Increased plasma YKL-40 is associated with risk of early death from cardiovascular disease, cancer, and other diseases in the general population.

show abstract

“…Rathcke et al (2009) proved that YKL-40 had a correlation with type 1 diabetic nephropathy, and suggested a role of YKL-40 in the occurrence of microvascular complications during renal vascular damage. Thus, they considered that YKL-40 might be useful as an independent marker (Nielsen et al, 2008;Rathcke et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Correlation between serum YKL-40 levels and albuminuria in type 2 diabetes

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We explored the correlation between serum YKL-40 levels and albuminuria in type 2 diabetes mellitus (T2DM) and its clinical significance. This study used a cross-sectional survey method. According to the American Diabetes Association 2007 Clinical Practice Recommendations, 738 patients with T2DM were divided into three groups: a normoalbuminuria group [albumin-to-creatinine ratio (ACR) <30 μg/mg, N = 360], a microalbuminuria group (ACR 30-300 μg/mg, N = 246), and a macroalbuminuria group (ACR ≥ 300 μg/mg, N = 332). The serum YKL-40 levels were determined by a quantitative sandwich enzyme-linked immunosorbent assay in all the cases and in 210 control subjects. Serum YKL-40 levels were significantly higher in the T2DM group vs the control group (P < 0.05), the macroalbuminuria group vs the microalbuminuria group (P < 0.05), and the microalbuminuria group vs the normoalbuminuria group (P < 0.05). Serum YKL-40 levels correlated with ACR in all 18597 Correlation between YKL-40 and albuminuria in T2DM ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 18596-18603 (2015) participants. Significant correlation of YKL-40 was found with ACR, 2-h plasma glucose, glycated hemoglobin, fasting blood glucose, homeostatic model assessment of insulin resistance index, systolic blood pressure, duration, diastolic blood pressure, age, triglycerides, and high-density lipoprotein cholesterol (r-values: 0.713, 0.524, 0.515, 0.467, 0.438, 0.409, 0.407, 0.374, 0.112, 0.097, and -0.123, respectively). ACR correlated with serum YKL-40 levels (Beta = 0.555, P < 0.001). YKL-40 may be involved in the occurrence and development of diabetic nephropathy and would be useful as a new marker for the disease.

show abstract

Plasma YKL-40

Cited by 134 publications

References 23 publications

Myokines in insulin resistance and type 2 diabetes

Myokines in insulin resistance and type 2 diabetes

Plasma YKL-40 and Total and Disease-Specific Mortality in the General Population

Correlation between serum YKL-40 levels and albuminuria in type 2 diabetes

Contact Info

Product

Resources

About